Personalized Immunotherapy for T Cell Lymphomas: From Immune Escape to Precision Therapeutics

Area of Science:

• Oncology
• Immunology
• Genetics

Background:

• Peripheral T cell lymphomas (PTCLs) present poor prognoses due to biological heterogeneity and chemotherapy resistance.
• Understanding PTCLs' immunogenomic and microenvironmental basis reveals diverse immune escape mechanisms.

Purpose of the Study:

• To review current literature on PTCL immune dysregulation and immunotherapy advances.
• To outline the biological rationale for novel immunotherapeutic strategies in PTCLs.
• To discuss biomarker-driven approaches for personalized PTCL treatment.

Main Methods:

• Literature synthesis of PTCL immunogenomics and microenvironment.
• Review of emerging immunotherapeutic strategies (e.g., checkpoint inhibitors, CAR-T cells).
• Discussion of molecular, transcriptomic, and microenvironmental profiling for biomarker discovery.

Main Results:

• PTCLs exhibit immune escape via defects in antigen presentation, apoptosis, adhesion, and tumor microenvironment remodeling.
• Novel immunotherapies show encouraging but inconsistent activity, necessitating personalized approaches.
• Biomarker-driven stratification is crucial for improving efficacy in PTCL treatment.

Conclusions:

• Deepened insight into PTCL biology supports novel immunotherapeutic strategies.
• Biomarker discovery through profiling enables adaptive trial designs and precision medicine.
• Future PTCL therapy aims to move beyond empiricism towards tailored, effective treatments.